Old and New Treatment Options in IgA Nephropathy and Henoch Schönlein Purpura Nephritis/IgA Vasculitis in Children

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Current Treatment Options in Pediatrics

• Publication date

  2019-06-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40746-019-00168-1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

  2019cited by this paper
• Podocytopathy in the mesangial proliferative immunoglobulin A nephropathy: new insights into the mechanisms of damage and progression.

  2019cited by this paper
• Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

  2019cited by this paper
• Analysis of seasonal tendencies in pediatric Henoch–Schönlein purpura and comparison with outbreak of infectious diseases

  2018cited by this paper
• New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine.

  2018cited by this paper
• Value of the Oxford classification of IgA nephropathy in children with Henoch–Schönlein purpura nephritis

  2018cited by this paper
• Brief Report: Rituximab for the Treatment of Adult‐Onset IgA Vasculitis (Henoch‐Schönlein)

  2018cited by this paper
• Presentation of pediatric Henoch–Schönlein purpura nephritis changes with age and renal histology depends on biopsy timing

  2018cited by this paper
• Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features

  2018cited by this paper
• Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature

  2018cited by this paper
• Should we really STOP treating patients with IgA nephropathy with steroids?

  2018cited by this paper
• Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study

  2018cited by this paper
• Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring

  2018cited by this paper
• IgA Nephropathy: A European Perspective in the Corticosteroid Treatment

  2018cited by this paper
• Treatment of IgA nephropathy: Recent advances and prospects.

  2018cited by this paper
• Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-Schönlein Purpura Nephritis

  2017cited by this paper
• The gut–kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition

  2017cited by this paper
• Remission of Hematuria Improves Renal Survival in IgA Nephropathy.

  2017cited by this paper
• Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature

  2017cited by this paper
• Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial

  2017cited by this paper
• Biomarkers and targeted new therapies for IgA nephropathy

  2017cited by this paper
• Clinical outcomes in children with Henoch–Schönlein purpura nephritis without crescents

  2017cited by this paper
• Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

  2017cited by this paper
• Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy.

  2017cited by this paper
• Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis

  2017cited by this paper
• A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy.

  2017cited by this paper
• Inflammation in IgA nephropathy

  2017cited by this paper
• New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura).

  2017cited by this paper
• Pathophysiology of IgA Nephropathy.

  2017cited by this paper
• Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression

  2016cited by this paper
• Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort

  2016cited by this paper
• Moderator's view: Treatment of IgA nephropathy-getting comfortable with uncertainty.

  2016cited by this paper
• Pro: STOP immunosuppression in IgA nephropathy?

  2016cited by this paper
• TO044A EUROPEAN REGISTRY OF HENOCH SCHOENLEINPURPURA NEPHRITIS IN CHILDREN TO DETECT RISK FACTORS FOR PROGRESSION

  2016cited by this paper
• B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis

  2016cited by this paper
• Effect of hematuria on the outcome of immunoglobulin A nephropathy with proteinuria

  2016cited by this paper
• Evidence-based clinical practice guidelines for IgA nephropathy 2014

  2016cited by this paper
• Con: STOP immunosuppression in IgA nephropathy.

  2016cited by this paper
• Proteinuria during Follow-Up Period and Long-Term Renal Survival of Childhood IgA Nephropathy

  2016cited by this paper
• Risk Factors Associated with Renal Involvement in Childhood Henoch-Schönlein Purpura: A Meta-Analysis

  2016cited by this paper
• Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

  2016cited by this paper
• Sibling Competition & Growth Tradeoffs. Biological vs. Statistical Significance

  2016cited by this paper
• Nationwide epidemiological survey of childhood IgA vasculitis associated hospitalization in the USA

  2016cited by this paper
• Clinical manifestations of Henoch–Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR)

  2015cited by this paper
• Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP).

  2015cited by this paper
• Role of complement in IgA nephropathy

  2015cited by this paper
• Mycophenolate mofetil plus prednisone for inducing remission of Henoch-Schönlein purpura nephritis: a retrospective study

  2015cited by this paper
• The difficulty in considering modifiable pathology risk factors in children with IgA nephropathy: crescents and timing of renal biopsy

  2015cited by this paper
• Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation

  2015cited by this paper
• Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

  2015cited by this paper
• Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

  2015cited by this paper
• Biopsy timing and Oxford classification variables in Childhood/Adolescent IgA nephropathy

  2015cited by this paper
• Prevention of nephritis in Henoch–Schönlein purpura

  2015cited by this paper
• Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.

  2015cited by this paper
• Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.

  2015cited by this paper
• Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis.

  2015cited by this paper
• Multimodal Surgical and Medical Treatment for Extensive Rhinocerebral Mucormycosis in an Elderly Diabetic Patient: A Case Report and Literature Review

  2014cited by this paper
• Using the Oxford classification of IgA nephropathy to predict long-term outcomes of Henoch–Schönlein purpura nephritis in adults

  2014cited by this paper
• Treatment of severe henoch-schonlein purpura nephritis with mycophenolate mofetil.

  2014cited by this paper
• Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments

  2014cited by this paper
• Successful Outcome of a Corticodependent Henoch-Schönlein Purpura Adult with Rituximab

  2014cited by this paper
• Refractory Henoch-Schönlein purpura: atypical aetiology and management.

  2013cited by this paper
• Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch–Schönlein purpura nephritis

  2013cited by this paper
• Rituximab treatment for adult purpura nephritis with nephrotic syndrome.

  2013cited by this paper
• Efficacy of cyclosporine A for steroid-resistant severe Henoch-Schönlein purpura nephritis.

  2013cited by this paper
• Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schönlein Purpura (HSP)

  2013cited by this paper
• Using the Oxford classification of IgA nephropathy to predict long-term outcomes of Henoch-Schonlein purpura nephritis in adults

  2013cited by this paper
• Prevention of renal disease in Henoch–Schönlein purpura: clear evidence against steroids

  2013cited by this paper
• Validity of the Oxford classification of IgA nephropathy in children

  2012cited by this paper
• Spontaneous remission in children with IgA nephropathy

  2012influential reference
• Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil

  2012cited by this paper
• KDIGO Clinical Practice Guideline for Glomerulonephritis

  2012cited by this paper
• Notice

  2012cited by this paper
• Validation of the Oxford classification of IgA nephropathy for pediatric patients from China

  2012cited by this paper
• Predicting Progression of IgA Nephropathy: New Clinical Progression Risk Score

  2012cited by this paper
• Long-term results of a randomized controlled trial in childhood IgA nephropathy.

  2011cited by this paper
• IgA nephropathy: progress before and since Berger.

  2011cited by this paper
• The pathophysiology of IgA nephropathy.

  2011cited by this paper
• Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report.

  2011cited by this paper
• Immunoglobulin A1 protease: A new therapeutic candidate for immunoglobulin A nephropathy

  2010cited by this paper
• Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura.

  2010cited by this paper
• Kawasaki disease and Henoch Schonlein purpura: changing trends at a tertiary care hospital in north India (1993–2008)

  2010cited by this paper
• The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults.

  2010cited by this paper
• Strict Blood-Pressure Control and Progression of Renal Failure in Children

  2010cited by this paper
• Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome

  2010cited by this paper
• Ultrasound of urinary system and urinary screening in 14 256 asymptomatic children in China

  2010cited by this paper
• Early high-dose immunosuppression in Henoch–Schönlein nephrotic syndrome may improve outcome

  2009cited by this paper
• Strict blood-pressure control and progression of renal failure in children.

  2009cited by this paper
• The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification.

  2009cited by this paper
• The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

  2009cited by this paper
• Pediatric IgA nephropathy: clinical and therapeutic perspectives.

  2008cited by this paper
• Mycophenolate mofetil treatment of crescentic Henoch–Schönlein nephritis with IgA depositions

  2008cited by this paper
• The improvement of renal survival with steroid pulse therapy in IgA nephropathy

  2008cited by this paper
• Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review

  2008cited by this paper
• Epidemiology of school urinary screening over a 30 year period in Tokyo

  2007cited by this paper
• Predictors of outcome in Henoch-Schönlein nephritis in children and adults.

  2006cited by this paper
• Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide

  2003cited by this paper
• Publisher's Note

  2003cited by this paper
• Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis

  2003cited by this paper
• What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis?

  2001cited by this paper

• No citing papers are available for this paper.